A practical reference on Cyclic heptapeptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-07-23 and is reviewed periodically as new material appears.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.
| Property | Value | Notes |
|---|---|---|
| Research code | PT-141 | Used in early literature before the generic name became common |
| Generic name | Bremelanotide | International nonproprietary name |
| Peptide class | Cyclic heptapeptide | Seven residues joined by a lactam bridge |
| Primary receptor | MC4R | Lower affinity reported at MC1R, MC3R and MC5R |
| Route studied clinically | Subcutaneous injection | Intranasal route was abandoned after pressor effects |
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
== Microbiology == The environment of the gingival sulcus is unlike any other location within the mouth. The ecosystem of the gingival sulcus is more anaerobic, and the site is filled with Gingival Crevicular Fluid (GCF). In the presence of periodontal disease, the gingival sulcus becomes a periodontal pocket and the oxidation reduction potential will decrease to low levels as the site is very anaerobic. At the same time, the gingival crevicular fluid would have increased by 147% when gingivitis is present and would have increased by up to 30-fold where periodontitis is present. While gingival crevicular fluid provides for the cellular defence and humoral factors to combat against the microbial insult, the gingival crevicular fluid also deliver novel substrates, in the form of proteins and glycoproteins, for bacterial metabolism. These include haeme containing molecules and iron, such as haemoglobin and transferrin. Dissimilarly to dental caries, many bacteria associated to periodontal disease cannot metabolise carbohydrates for energy (they are asaccharolytic) and are proteolytic too. One effect of proteolysis is that the pH of the gingival pocket with periodontal disease will increase and becomes slightly alkaline at around a pH level of 7.4 – 7.8 as compared to relatively neutral pH values, around a pH level of 6.9, when the gingival is healthy. In alkaline growth conditions, the enzyme activity and growth activity of periodontal pathogens, like Porphyromonas gingivalis.
These cleaning methods may include soaking powdered biomineral samples in bleach prior to extracting amino acids, destroying the amino acids in the more porous, open areas while leaving the fraction trapped inside the grains unscathed.
== Activation == Aggrecan degrading enzymes such as ADAMTS4 and ADAMTS5 are initially produced in an inactive state to avoid unwanted cartilage breakdown. This is the bodys way of protecting itself from over degradation as cartilage does provide use to cushion the joints. In order to activate the enzymes, separate enzymes called proprotein converses or serine proteinases will remove a small blocking segment from the aggrecanase protein called aggrecanase propeptides. The proprotein convertases will break the peptide bond at the amino acid pattern R/K–Xn–R/K–Y. Where the R/K are indicating either arginine or lysine, X is indicating any amino acid could be present, and n is indicating the varying amount of amino acids that are possible for the in between :zero, two, four, or six. The activation can occur at different locations based on where the enzymes are in and around the cell. These enzymes can be found inside the cell, on the cell surface, and outside the cell in the surrounding tissue. This allows enzymes such as furin to activate aggrecans in locations such as the trans Golgi network or the extracellular matrix.
To do this, known controls are tested consecutively with unknown samples. By comparing the readouts of the controls with their known profiles the instrument can be confirmed to have been working properly at the time the unknowns were tested. Standards are also used to determine the instrument's limit of detection and limit of quantification for various common substances. Calculated quantities must be above the limit of detection to be confirmed as present and above the limit of quantification to be quantified. If the value is below the limit the value is not considered reliable.
Both religions revere John the Baptist, Saint George, and Elijah. Druze, believe that Elijah came back as John the Baptist, or as Saint George, since they belief in reincarnation and the transmigration of the soul, Druze believe that El Khidr and John the Baptist and Saint George are one and the same. Elijah is a central figure of Druzism, and he considered patron of the Druze people. Due to the Christian influence on the Druze faith, two Christian saints become the Druze's favorite venerated figures: Saint George and the Prophet Elijah. Thus, in all the villages inhabited by the Druze and Christians in central Mount Lebanon, a Christian church or Druze maqam is dedicated to either the Prophet Elijah or Saint George. The reverence for Saint George, who is often identified with Al-Khidr, is deeply integrated into various aspects of Druze culture and religious practices. According to scholar Ray Jabre Mouawad, the Druze appreciated the two saints for their bravery, Saint George because he confronted the dragon and the Prophet Elijah because he competed with the pagan priests of Baal and won over them. In both cases the explanations provided by Christians are that Druzes were attracted to warrior saints that resemble their own militarized society. The Druze environment influenced in turn the Christians, and Christians living among Druze started to adopt the same word for some of their churches, using maqām instead of kanīsah (church). Saint George is seen as a guardian of the Druze community and a symbol of their enduring faith and resilience.
Sources: en.wikipedia.org
Governments worldwide have created provisions for granting access to drugs prior to approval for patients who have exhausted all alternative treatment options and do not match clinical trial entry criteria. Often grouped under the labels of compassionate use, expanded access, or named patient supply, these programs are governed by rules which vary by country defining access criteria, data collection, promotion, and control of drug distribution. Within the United States, pre-approval demand is generally met through treatment IND (investigational new drug) applications (INDs), or single-patient INDs. These mechanisms, which fall under the label of expanded access programs, provide access to drugs for groups of patients or individuals residing in the US. Outside the US, Named Patient Programs provide controlled, pre-approval access to drugs in response to requests by physicians on behalf of specific, or "named", patients before those medicines are licensed in the patient's home country. Through these programs, patients are able to access drugs in late-stage clinical trials or approved in other countries for a genuine, unmet medical need, before those drugs have been licensed in the patient's home country. Patients who have not been able to get access to drugs in development have organized and advocated for greater access.
The successful incorporation of a third base pair is a significant breakthrough toward the goal of greatly expanding the number of amino acids which can be encoded by DNA, from the existing 20 amino acids to a theoretically possible 172, thereby expanding the potential for living organisms to produce novel proteins. In the future, these unnatural base pairs could be synthesised and incorporated into oligonucleotides via DNA printing methods.
Since bats are mammals that can fly, they are considered to be liminal beings in various traditions. In many cultures, including in Europe, bats are associated with darkness, death, witchcraft, and malevolence. Among Native Americans such as the Creek, Cherokee and Apache, the bat is identified as a trickster. An East Nigerian tale tells that the bat developed its nocturnal habits after causing the death of his partner, the bush rat, and now hides by day to avoid arrest. More positive depictions of bats exist in some cultures. In China, bats have been associated with happiness, joy and good fortune, and symbolise the "Five Blessings": longevity, riches, health, love of virtue and a peaceful passing away. The bat is sacred in Tonga and is considered the property of the king. Mayan people associated bats with the gateway to the realm of the gods since they live in caves. In the Zapotec civilisation, the bat god presided over corn and fertility.
== Adverse effects == There is a need for controlled clinical trials before the safety of ibogaine can be established; existing evidence, largely from uncontrolled case reports, links it to significant acute and long-term adverse events (especially cardiac issues like QTc prolongation), including fatalities. It should only be used in medically supervised settings with thorough screening and continuous cardiac and psychiatric monitoring. Ibogaine can cause various cardiovascular changes (e.g., slowed heart rate, blood pressure shifts), neurological effects (ataxia, tremor, mania), and rare but serious complications, including arrhythmias, respiratory failure, and death, especially when combined with opioids or in patients with underlying conditions. Cardiac risks likely occur through hERG channel blockade leading to QT prolongation and arrhythmias; the synthetic analog 18-MC appears to produce much less of this dangerous effect despite similar binding affinity. A 2022 review found 58 ibogaine-associated emergencies, including 38 deaths. Two of these deaths occurred in the setting of clinical studies. According to a 2012 estimate, 1 in every 300 patients who take ibogaine die.
=== Pasteurized donkey milk === Donkey milk is pasteurized in a closed circuit of pasteurization and bottling (aseptic) at least 72 °C for 15 seconds or equivalent times and temperatures. In the case of pasteurization in discontinuous systems, the temperature must be higher depending on the method used and the type of plant and destination.
Sources: en.wikipedia.org
== Structure == The human protein acid transporter (hPAT1) is 5585 base pairs long and codes for a protein 476 amino acids long. The transporter has nine transmembrane regions where the amino terminus faces the cytoplasm. The rat protein acid transporter (rPAT1) has been widely studied and an 85% amino acid sequence match was found between hPAT1 and rPAT1. The hPAT1 gene is located on chromosome 5q31-33 and has 11 exons that are coding regions. Its translation site begins in exon 2 and exon 11 contains the termination site.
As a French protectorate, Bizerte, Tunisia, was a major French base. Tunisian troops, mostly RTT (Régiment de Tirailleurs Tunisiens), were sent to Indochina. Part of French Indochina, then part of the French Union and later an associated state, Laos fought the communists along with French forces. The role played by Laotian troops in the conflict was depicted by veteran Pierre Schoendoerffer's famous 317th Platoon released in 1964. The French Indochina state of Cambodia also played a role during the Indochina War through the Khmer Royal Army, which had been formed in 1946 in an agreement signed with the French. While Bảo Đại's State of Vietnam (formerly Annam, Tonkin, Cochinchina) had the Vietnamese National Army supporting the French forces, some minorities were trained and organized as regular battalions (mostly infantry tirailleurs) that fought with French forces against the Việt Minh. The Tai Battalion 2 (BT2, 2e Bataillon Thai) is infamous for its desertion during the siege of Dien Bien Phu. Propaganda leaflets written in Tai and French sent by the Việt Minh were found in the deserted positions and trenches. Such deserters were called the Nam Yum rats by Bigeard during the siege, as they hid close to the Nam Yum river during the day and searched at night for supply drops. Another allied minority was the Muong people (Mường). The 1st Muong Battalion (1er Bataillon Muong) was awarded the Croix de guerre des théâtres d'opérations extérieures after the victorious Battle of Vĩnh Yên in 1951.
=== Therapeutic reactivation and gene therapy === While increasing p53 levels might appear beneficial for treating cancer, sustained p53 activation can cause premature aging. A more promising approach involves restoring normal, endogenous p53 function. In some tumor types, this leads to regression via apoptosis or normalization of cell growth. The first commercial gene therapy, Gendicine, was approved in China in 2003 for head and neck squamous cell carcinoma. It delivers a functional copy of the TP53 gene using a modified adenovirus. The small-molecule inhibitor MI-63 can bind to MDM2, blocking its interaction with p53 and reactivating p53 in cancers where its function is suppressed. A p53 reactivator rezatapopt is in clinical trials in patients whose tumors show the common Y220C mutation of p53, and restores anti-cancer effectiveness to the mutated protein.
Sorption (including granular activated carbon, biochar, and ion exchange resins) Membrane filtration (reverse osmosis, nanofiltration) Foam fractionation Precipitation/flocculation/coagulation Constructed wetlands Destructive methods
Russia attacked Kyiv with missiles and drones. Later in the day, at least nine people were killed and 29 others injured in a missile strike in Kryvyi Rih. Explosions were reported in Crimea and Krasnodar Krai according to local media. A Russian S-300 near Belbek airfield and two S-400s near Belbek and Sevastopol were destroyed according to Ukrainian officials. The US pledged another Patriot battery to Ukraine. Russia deployed S-500 batteries to Crimea, according to the HUR. A Ukrainian soldier claimed to have shot down a cruise missile using a machine gun, during a Russian air attack on Kyiv.
Sources: en.wikipedia.org
The code designates bremelanotide, a cyclic heptapeptide melanocortin receptor agonist. It served as an internal research identifier before the compound entered formal clinical development. The code and the generic name refer to the same molecule.
MC4R is generally described as the principal target, based on binding affinity and functional assays. Activity at MC1R, MC3R and MC5R is reported as weaker. Receptor selectivity is one reason the compound was pursued for central rather than vascular effects.
Both are synthetic melanocortin analogues built on a similar cyclic peptide scaffold. Bremelanotide is described in the literature as a metabolite-derived analogue of melanotan II rather than the same substance. The two differ in terminal modifications, which affect half-life and receptor profile.
It is a synthetic cyclic peptide that acts as an agonist at melanocortin receptors. It is not a hormone replacement therapy and not a vasodilator in the usual clinical sense, although it does affect vascular tone. Chemically it belongs to the melanocortin analogue family.